Funding for this research was provided by:
Received: 13 August 2021
Accepted: 6 November 2021
First Online: 24 November 2021
: Study materials were reviewed and approved by the New England Institutional Review Board in November 2018 and July 2019. All patients gave their informed consent to be included in the study.
: All patients gave their informed consent for the results of the study to be published.
: ESD has received research funding from AstraZeneca, Adare/Ellodi, Allakos, Arena, GSK, Meritage, Miraca, Nutricia, Celgene/Receptos/BMS, Regeneron, and Shire/Takeda, and educational grants from Allakos, Banner, and Holoclara. ESD has also served as a consultant for AstraZeneca, Abbott, Abbvie, Adare/Ellodi, Aimmune, Allakos, Amgen, Arena, Avir, Biorasi, Calypso, Celgene/Receptos/BMS, Celldex, Eli Lilly, EsoCap, GSK, Gossamer Bio, Holoclara, Landos, Morphic, Nutricia, Parexel/Calyx, Regeneron, Revolo, Robarts/Alimentiv, Salix, Sanofi, and Shire/Takeda. CNH, SOQ, and CD are employees of and own stocks and shares in AstraZeneca. JRB and OM are employees of IQVIA Real World Solutions, Patient Centered Solutions, which received funding from AstraZeneca to complete the study. AFS has served as a consultant for IQVIA.